Integra Lifesciences Holdings (IART) Operating Leases (2019 - 2026)
Integra Lifesciences Holdings' Operating Leases history spans 7 years, with the latest figure at $177.1 million for Q4 2025.
- On a quarterly basis, Operating Leases rose 6.08% to $177.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $177.1 million, a 6.08% increase, with the full-year FY2025 number at $177.1 million, up 6.08% from a year prior.
- Operating Leases hit $177.1 million in Q4 2025 for Integra Lifesciences Holdings, up from $174.8 million in the prior quarter.
- Over the last five years, Operating Leases for IART hit a ceiling of $184.2 million in Q2 2024 and a floor of $87.8 million in Q1 2022.
- Historically, Operating Leases has averaged $153.6 million across 5 years, with a median of $167.9 million in 2023.
- Biggest five-year swings in Operating Leases: fell 19.77% in 2022 and later surged 95.55% in 2023.
- Tracing IART's Operating Leases over 5 years: stood at $90.3 million in 2021, then soared by 90.46% to $172.0 million in 2022, then increased by 5.86% to $182.1 million in 2023, then decreased by 8.35% to $166.9 million in 2024, then increased by 6.08% to $177.1 million in 2025.
- Business Quant data shows Operating Leases for IART at $177.1 million in Q4 2025, $174.8 million in Q3 2025, and $159.3 million in Q2 2025.